HAE
$70.11
Haemonetics
$.01
.01%
Earnings Details
2nd Quarter September 2025
Thursday, November 6, 2025 6:00:00 AM
Tweet Share Watch
Summary

Haemonetics Raises Revenue Guidance Above Estimates

Haemonetics (HAE) reported 2nd Quarter September 2025 earnings of $1.27 per share on revenue of $327.3 million. The consensus earnings estimate was $1.12 per share on revenue of $311.1 million. Revenue fell 5.3% compared to the same quarter a year ago.

The company said in its earnings presentation it expects fiscal 2026 earnings of $4.80 to $5.00 per share on revenue of $1.31 billion to $1.35 billion. The company's previous guidance was earnings of $4.70 to $5.00 per share on revenue of $1.28 billion to $1.32 billion, and the current consensus earnings estimate is $4.80 per share on revenue of $1.30 billion for the year ending March 31, 2026.

Haemonetics Corp is a healthcare company that provides blood management solutions to its customers. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals.

Results
Reported Earnings
$1.27
Earnings Whisper
-
Consensus Estimate
$1.12
Reported Revenue
$327.3 Mil
Revenue Estimate
$311.1 Mil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Financial release and supplemental presentation accessible online

BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 6, 2025.

Conference Call and Webcast Information:

  • Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event start time is recommended.
  • Live webcast: Access here or through the Investor Relations section of the Haemonetics website.

A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on November 6, 2025 and will remain accessible for one year via the webcast link above.

Earnings Materials:
Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:

ABOUT HAEMONETICS

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com

Investor Contacts:


Olga Guyette, Vice President-Investor Relations & Treasury     

David Trenk, Manager-Investor Relations

(781) 356-9763                                             

(203) 733-4987

olga.guyette@haemonetics.com                   

david.trenk@haemonetics.com  



Media Contact: 


Josh Gitelson, Sr. Director-Global Communications 


(781) 356-9776 


josh.gitelson@haemonetics.com 


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-corporation-announces-second-quarter-fiscal-2026-financial-results-available-on-investor-relations-website-302606803.html

SOURCE Haemonetics Corporation